Điều trị kháng nhiễm ở bệnh nhân béo phì – "đơn giản là gấp đôi?"

Alobaid AS, Wallis SC, Jarret P et al (2017) Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients. Antimicrob Agents Chemother 61(3):e01276-16 Blot SI, Pea F, Lipman J (2014) The effect of pathophysiology on pharmacokinetics in the critically ill patient—concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 77:3–11 Boyd SE, Charani E, Lyons T et al (2016) Information provision for antibacterial dosing in the obese patient: a sizeable absence? J Antimicrob Chemother 71:3588–3592 Brill MJ, Houwink AP, Schmidt S et al (2014) Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother 69:715–723 Brinkmann A, Röhr AC, Frey OR et al (2018) S2k guidelines of the PEG on calculated parenteral initial treatment of bacterial diseases in adults: focused summary and supplementary information on antibiotic treatment of critically ill patients. Anaesthesist 67(12):936–949 Burau D, Petroff D, Simon P et al (2019) Drug combinations and impact of experimental conditions on relative recovery in in vitro microdialysis investigations. Eur J Pharm Sci 127:252–260 Burnham JP, Kirby JP, Kollef MH (2016) Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review. Intensive Care Med 42(12):1899–1911 Chung EK, Cheatham SC, Fleming WR et al (2017) Population pharmacokinetics and pharmacodynamics of meropenem in nonobese, obese, and morbidly obese patients. J Clin Pharmacol 257(3):356–368 Cojutti P, Pai MP, Pea F (2018) Population pharmacokinetics and dosing considerations for the use of linezolid in overweight and obese adult patients. Clin Pharmacokinet 57:989–1000 Dorn C, Petroff D, Neumann N et al (2019) Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients—a controlled clinical trial. J Antimicrob Chemother 74(8):2335–2340 Ehmann L, Simon P, Busse D et al (2020) Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2020.04.009 European Committee on Antimicrobial Susceptibility Testing (2019) Breakpoint tables for interpretation of MIcs and zone diameters, version 9.0. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf. Zugegriffen: 21. Nov. 2019 Falagas ME, Vouloumanou EK, Samonis G et al (2016) Fosfomycin. Clin Microbiol Rev 29(2):321–347 Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49:71–87 Jager NGL, van Hest RM, Lipman J et al (2019) Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. Expert Rev Clin Pharmacol 12(7):623–634 Jain R, Chung S, Jain L et al (2011) Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 90:77–89 Joukhadar C, Derendorf H, Müller M et al (2001) Microdialysis—a novel tool for clinical studies of anti-infective agents. Eur J Clin Pharmacol 57:211–219 Kees MG, Weber S, Kees F et al (2011) Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother 66:2330–2335 Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut (2018) Prävention postoperativer Wundinfektionen. Bundesgesundheitsblatt 61:448–473 Melgaard L, Hersini KJ, Gazerani P et al (2013) Retrodialysis: a review of experimental and clinical applications of reverse microdialysis in the skin. Skin Pharmacol Physiol 26:160–174 Meng L, Mui E, Holubar MK et al (2017) Comprehensive guidance for antibiotic dosing in obese adults. Pharmacotherapy 37:1415–1431 Minichmayr IK (2017) Pharmacometrics-based Evaluation of Antibiotic Target-site Exposure to Improve Dosing Regimens in Special Populations. Freie Universität Berlin Minichmayr IK, Schaeftlein A, Kuti JL et al (2017) Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically ill patients. Clin Pharmacokinet 56:617–633 Palma EC, Meinhardt NG, Stein AT et al (2018) Efficacious cefazolin prophylactic dose for morbidly obese women undergoing bariatric surgery based on evidence from subcutaneous microdialysis and populational pharmacokinetic modeling. Pharm Res 35(6):116 Plock N, Kloft C (2005) Microdialysis—theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci 25:1–24 Simmel F, Kirbs C, Erdogan Z et al (2013) Pilot investigation on long-term subcutaneous microdialysis: proof of principle in humans. AAPS J 15:95–103 Simon P, Busse D, Petroff D et al (2020) Linezolid concentrations in plasma and subcutaneous tissue are reduced in obese patients, resulting in a higher risk of underdosing in critically ill patients: a controlled clinical pharmacokinetic study. J Clin Med 9(4):E1067 Simon P, Petroff D, Dorn C et al (2019) Measurement of soft tissue drug concentrations in morbidly obese and non-obese patients—a prospective, parallel group, open-labeled, controlled, phase IV, singlecenter clinical trial. Contemp Clin Trials Commun 15:100375 Ståhle L, Arner P, Ungerstedt U (1991) Drug distribution studies with microdialysis III: extracellular concentration of caffeine in adipose tissue in man. Life Sci 49:1853–1858 Udy AA, Varghese JM, Altukroni M et al (2012) Subtherapeutic initial b‑lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142:30–39 Wacha H, Hoyme U, Isenmann R et al (2010) Perioperative Antibiotika-Prophylaxe Empfehlungen einer Expertenkommission der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. Chemother J 19(3):70–84